SR TR

SCIENTIFIC REGISTRY 약 TRANSPLANT RECIPIENTS Waitlist and posttransplant outcomes of candidates with LVAD: Comparison of old and new heart allocation policies

Colvin M, Ahn Y, Hall S, Walsh M, Israni A

Disclosures

Monica Colvin, MD, MS Professor of Medicine Advanced Heart Failure, Transplant, and MCS Associate Director, Heart Transplant University of Michigan/Michigan Medicine, Ann Arbor, MI US Senior Lead for Heart, SRTR

I have no financial relationships to disclose within the past 12 months relevant to my presentation.My presentation does not include discussion of off-label or investigational use.I do not intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

This work was supported wholly or in part by HRSA contract 75R60220C00011. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of HHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.



Introduction

The new heart allocation policy took effect in October 2018. The new risk stratification scheme prioritizes patients with short-term devices, raising concern that candidates with durable left ventricular assist devices (LVADs) may be disadvantaged and posttransplant outcomes compromised. We compared trends in LVAD use and outcomes under the old and new policies.



Methods

Waitlist

Cohort:

- <u>Group 1</u>: 1454 newly listed adult heart candidates with LVAD from 8/3/2016 to 10/17/2017 were followed for a year
- <u>Group 2</u>: 1341 newly listed adult heart candidates with LVAD from 10/18/2018 to 12/31/2019 were followed for a year

Analysis: Unadjusted cumulative incidence for 1-year waitlist outcomes

Posttransplant

Cohort:

- <u>Group 1</u>: 1601 adult heart recipients on LVAD on the waitlist received transplants during 8/3/2016-10/17/2017 and were followed for a year
- <u>Group 2</u>: 1197 adult heart recipients on LVAD on the waitlist received transplants during 10/18/2018-12/31/2019 and were followed for a year

Analysis: Unadjusted Kaplan-Meier survival curves for 30 days, 6 months, and 1 year



Results: Demographics

		Group 1	Group 2
Age (years)	18-34	9.4	10.1
	35-49	21.8	24.8
	50-64	50.4	50.5
	65+	18.4	14.6
Sex	Male	80.3	78.7
	Female	19.7	21.3
Race	White	61.5	58.2
	Black/African American	26.9	30.0
	Hispanic	7.8	8.1
	Asian/Pacific Islander	3.1	3.1
	Other/unknown	0.8	0.5
Wait time (days)	0-<30	17.3	22.0
	30-<60	17.4	13.3
	60-<180	14.9	12.1
	180-<270	11.2	7.6
	270-<365	9.4	8.1
	365+	29.8	37.0



Results: Waitlist Outcomes by Status

	Group 1						Group 2						
	Status 1A	Status 1B	Status 2	Inactive	Status 1	Status 2	Status 3	Status 4	Status 5	Status 6	Inactive		
Still Waiting	46	326	33	26	0	6	51	403	1	21	13		
Died	25	20	5	6	2	6	4	12	0	1	2		
Transplanted	308	469	15	22	32	108	188	352	0	5	11		
Removed*	46	83	11	13	1	6	28	76	0	7	5		
Total	425	898	64	67	35	126	271	843	1	34	31		




Results: Waitlist Outcomes

Table 1. One-year outcomes for newly listed adult candidates waiting for heart transplant who were on LVAD

	Gro	up 1	Group 2		
	Count	Percent	Count	Percent	
Total LVAD candidates	1454	100.00	1341	100.00	
Still Waiting	431	29.6	495	36.9	
Died	56	3.9	27	2.0	
Transplanted	814	56.0	696	51.9	
Removed*	153	10.5	123	9.2	

Removed*: candidates who have a removal code other than transplant or death by their followup date.

Followup date: 1 year after transplant. p-value: 0.75



Group 1: newly waitlisted during $\frac{8}{3}2016-\frac{10}{17}2017$ and followed for a year. Group 2: newly waitlisted during $\frac{10}{18}2018-\frac{12}{31}2019$ and followed for a year.

Results: Posttransplant Survival

Table 2. Outcomes at 30 days, 6 months, and 1 year post-transplant

	Р				
	Gro	up 1	Gro		
	Count	Percent	Count	Percent	p-values
Total LVAD recipients	1601	100.0	1197	100.0	
Alive at 30 days	1537	96.0	1147	95.8	0.8
Died within 30 days	64	4.0	50	4.2	
Alive at 6 months	1495	93.4	1098	91.7	0.1
Died within 6 months	106	6.6	99	8.3	
Alive at 1 year	1462	91.3	1076	89.9	0.2
Died within 1 year	139	8.7	121	10.1	

30 days data is from the date of transplant to 30 days.


6 months data is from the date of transplant to 6 months.

1 year data is from the date of transplant to 1 year.

p-values are from unadjusted Kaplan-Meier analyses.



Results: Post-transplant Survival



Group 1: received a transplant during 8/3/2016-10/17/2017 and followed for a year. Group 2: received a transplant during 10/18/2018-12/31/2019 and followed for a year



Discussion

- Since implementation of the new policy, the proportion of heart transplant candidates with LVAD who received transplants has decreased 25%
- The proportion of candidates still awaiting transplant also increased under the new policy
- Most LVAD patients listed as status 4, of which 42% received transplants
- Although waitlist mortality has declined in LVAD patients since the new policy, posttransplant mortality has increased slightly, possibly due to sicker LVAD patients
- Although not statistically significant, this trend bears monitoring given the shift toward short-term devices





Transplantation

Director Jon Snyder, PhD, MS

Investigators Bertram Kasiske, MD FACP Ajay Israni, MD, MS Allyson Hart, MD, MS

> Program Caitlyn Nystedt, MPH, PMP Manager

Sr. Administrative Pamela Giles Assistant

> Medical Mary Van Beusekom. MS. ELS **F**ditor

Marketing & Mona Shater, MA Comms. Amy Ketterer Tonya Eberhart

> **Project** Katherine Audette, MS Managers Michael Conboy, Bryn Thompson, MPH

Project Chris Folken Coordinator

Sr. Manager, David Zaun, MS **Biostatistics**

Manager, Melissa Skeans, MS **Biostatistics**

Principal Nicholas Salkowski, PhD Biostatisticians Andrew Wey, PhD Sr. Biostatistician Donnie Musgrove, PhD **Biostatisticians** David Schladt, MS Tim Weaver, MS Yoon Son Ahn, MS Jon Miller, PhD, MPH IT. Web. Ryan Follmer Database, Carl Fils-Aime Simulation Mark Fredrickson Patrick Johnson

Eugene Shteyn, MS Matthew Tabaka

Joshua Pyke, PhD

Greta Knefelkamp





SCIENTIFIC REGISTRY 으 TRANSPLANT RECIPIENTS

Contact us: SRTR@SRTR.org

Follow us:



in

Scientific Registry of Transplant Recipients

